nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

07.05.2021 | Original Article

Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia

verfasst von: Yomna H. Youssef, Sara M. Makkeyah, Ahmed F. Soliman, Nefissa H. Meky

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Asparaginase (ASNase) is a key component in the treatment protocols of childhood acute lymphoblastic leukemia (ALL). Asparagine synthetase (ASNS) and the basic region leucine zipper activating transcription factor 5 (ATF5) mediate the anti-leukemic effect of ASNase. Only a few reports studied the association between polymorphisms in these genes and treatment-related toxicity and response. Therefore, the current study aimed to investigate the association of ASNS and ATF5 polymorphisms with the susceptibility to ASNase-related toxicity and disease outcome in a population of childhood ALL Egyptian patients.

Methods

In this study, 88 children with ALL were enrolled and genotyped for ASNS T629A and ATF5 C362T polymorphisms using allelic discrimination assay.

Results

The studied polymorphisms did not associate with hypersensitivity or thrombosis, while the ATF5 C362T polymorphism was associated significantly with decreased ASNase-associated pancreatitis (AAP) risk under the dominant model. Patients carrying TT/CT genotypes of ATF5 C362T polymorphism had a significantly better overall survival (OS) and longer event-free survival (EFS) compared to patients with CC genotype. Multivariate analysis confirmed the independent prognostic value of the ATF5 C362T dominant model.

Conclusion

ATF5 362TT and CT genotypes were associated with decreased risk to develop AAP and better disease outcome demonstrating a low risk for events and superior survival.

Nur mit Berechtigung zugänglich

Grigoropoulos NF, Petter R, Van't Veer MB, Scott MA, Follows GA (2013) Leukemia update. Part 1: diagnosis and management. BMJ 346:f1660. https://doi.org/10.1136/bmj.f1660

Vagace JM, de la Maya MD, Caceres-Marzal C, Gonzalez de Murillo S, Gervasini G (2012) Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia/lymphoma. Crit Rev Oncol Hematol 84:274–286. https://doi.org/10.1016/j.critrevonc.2012.04.003CrossRefPubMed

Narta UK, Kanwar SS, Azmi W (2007) Pharmacological and clinical evaluation of l-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 61:208–221. https://doi.org/10.1016/j.critrevonc.2006.07.009CrossRefPubMed

Kawedia JD, Rytting ME (2014) Asparaginase in acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 14:S14–S17. https://doi.org/10.1016/j.clml.2014.06.017CrossRefPubMed

Muller HJ, Boos J (1998) Use of l-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28:97–113. https://doi.org/10.1016/s1040-8428(98)00015-8CrossRefPubMed

Estes DA, Lovato DM, Khawaja HM, Winter SS, Larson RS (2007) Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol 139:20–30. https://doi.org/10.1111/j.1365-2141.2007.06763.xCrossRefPubMed

Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer LM (2005) A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res 65:291–299PubMed

Al Sarraj J, Vinson C, Thiel G (2005) Regulation of asparagine synthetase gene transcription by the basic region leucine zipper transcription factors ATF5 and CHOP. Biol Chem 386:873–879. https://doi.org/10.1515/BC.2005.102CrossRefPubMed

Watatani Y, Kimura N, Shimizu YI, Akiyama I, Tonaki D, Hirose H et al (2007) Amino acid limitation induces expression of ATF5 mRNA at the post-transcriptional level. Life Sci 80:879–885. https://doi.org/10.1016/j.lfs.2006.11.013CrossRefPubMed

10.

Watatani Y, Ichikawa K, Nakanishi N, Fujimoto M, Takeda H, Kimura N et al (2008) Stress-induced translation of ATF5 mRNA is regulated by the 5′-untranslated region. J Biol Chem 283:2543–2553. https://doi.org/10.1074/jbc.M707781200CrossRefPubMed

11.

Pui CH, Mullighan CG, Evans WE, Relling MV (2012) Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120:1165–1174. https://doi.org/10.1182/blood-2012-05-378943CrossRefPubMedPubMedCentral

12.

Lopez-Santillan M, Iparraguirre L, Martin-Guerrero I, Gutierrez-Camino A, Garcia-Orad A (2017) Review of pharmacogenetics studies of l-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene. Drug Metab Pers Ther 32:1–9CrossRef

13.

Gervasini G, Vagace JM (2012) Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia. Front Genet 3:249CrossRef

14.

Wolthers BO, Frandsen TL, Abrahamsson J, Albertsen BK, Helt LR et al (2017) Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. Leukemia 31:325–332CrossRef

15.

Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB (2009) Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer 53:162–167. https://doi.org/10.1002/pbc.22076CrossRefPubMedPubMedCentral

16.

Zia AN, Chitlur M (2013) Management of thrombotic complications in acute lymphoblastic leukemia. Indian J Pediatr 80:853–862. https://doi.org/10.1007/s12098-013-1158-9CrossRefPubMed

17.

Akagi T, Yin D, Kawamata N, Bartram CR, Hofmann WK, Song JH et al (2009) Functional analysis of a novel DNA polymorphism of a tandem repeated sequence in the asparagines synthetase gene in acute lymphoblastic leukemia cells. Leuk Res 33:991–996CrossRef

18.

Rousseau J, Gagne V, Labuda M, Beaubois C, Sinnett D, Laverdiere C et al (2011) ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood 118:5883–5890. https://doi.org/10.1182/blood-2011-05-355560CrossRefPubMedPubMedCentral

19.

Ben Tanfous M, Sharif-Askari B, Ceppi F, Laaribi H, Gagné V, Rousseau J et al (2015) Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. Clin Cancer Res 21:329–334. https://doi.org/10.1158/1078-0432.CCR-14-0508CrossRefPubMed

20.

Bava KA, Gromiha MM, Uedaira H, Kitajima K, Sarai A (2004) ProTherm, version 4.0: thermodynamic database for proteins and mutants. Nucleic Acids Res 32:D120–D121. https://doi.org/10.1093/nar/gkh082

21.

Capriotti E, Fariselli P, Casadio R (2005) I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res 33:W306-310. https://doi.org/10.1093/nar/gki375CrossRefPubMedPubMedCentral

22.

Verma N, Kumar K, Kaur G, Anand S (2007) l-Asparaginase: a promising chemotherapeutic agent. Crit Rev Biotechnol 27:45–62CrossRef

23.

Silverman LB, Gelber RD, Dalton VK et al (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211–1218CrossRef

24.

Moghrabi A, Levy DE, Asselin B et al (2007) Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95–01 for children with acute lymphoblastic leukemia. Blood 109:896–904CrossRef

25.

Lomelino CL, Andring JT, McKenna R, Kilberg MS (2017) Asparagine synthetase: function, structure, and role in disease. J Biol Chem 292:19952–19958. https://doi.org/10.1074/jbc.R117.819060CrossRefPubMedPubMedCentral

26.

Greene LA, Lee HY, Angelastro JM (2009) The transcription factor ATF5: role in neurodevelopment and neural tumors. J Neurochem 108:11–22. https://doi.org/10.1111/j.1471-4159.2008.05749.xCrossRefPubMed

27.

Du K, Sharma M, Lukacs GL (2005) The Delta F508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 12:17–25. https://doi.org/10.1038/nsmb882CrossRefPubMed

28.

Mayer S, Rüdiger S, Ang HC, Joerger AC, Fersht AR (2007) Correlation of levels of folded recombinant p53 in Escherichia coli with thermodynamic stability in vitro. J Mol Biol 372:268–276. https://doi.org/10.1016/j.jmb.2007.06.044CrossRefPubMed

29.

Singh SM, Kongari N, Cabello-Villegas J, Mallela KM (2010) Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-beta aggregates. Proc Natl Acad Sci 107:15069–15074. https://doi.org/10.1073/pnas.1008818107CrossRefPubMedPubMedCentral

30.

Stams WA, den Boer ML, Holleman A, Appel IM, Beverloo HB, van Wering ER et al (2005) Asparagine synthetase expression is linked with l-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 105:4223–4225CrossRef

31.

Aslanian AM, Fletcher BS, Kilberg MS (2001) Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J 357:321–328CrossRef

32.

Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D (2007) Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Investig 117:1049–1057CrossRef

33.

Horikoshi A, Takei K, Iriyama N, Uenogawa K, Ishizuka H, Shiraiwa H et al (2009) Effect of l-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma. Acta Haematol 122:54–57. https://doi.org/10.1159/000243725CrossRefPubMed

34.

Li Y, Zhang X, Hu T, Han L, Li R, Wen J et al (2014) Asparagine synthetase expression and its potential prognostic value in patients with NK/T cell lymphoma. Oncol Rep 32:853–859. https://doi.org/10.3892/or.2014.3237CrossRefPubMed

35.

Pastorczak A, Fendler W, Zalewska-Szewczyk B, Górniak P, Lejman M, Trelińska J et al (2014) Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment. Leuk Res 38:180–183. https://doi.org/10.1016/j.leukres.2013.10.027CrossRefPubMed

36.

Grimes AC, Chen Y, Bansal H, Aguilar C, Perez Prado L, Quezada G et al (2021) Genetic markers for treatment-related pancreatitis in a cohort of Hispanic children with acute lymphoblastic leukemia. Support Care Cancer 29:725–731. https://doi.org/10.1007/s00520-020-05530-wCrossRefPubMed

37.

Angelastro JM, Canoll PD, Kuo J, Weicker M, Costa A, Bruce JN et al (2006) Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene 25:907–916CrossRef

38.

Dluzen D, Li G, Tacelosky D, Moreau M, Liu DX (2011) BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner. J Biol Chem 286:7705–7713. https://doi.org/10.1074/jbc.M110.207639CrossRefPubMedPubMedCentral

39.

Monaco SE, Angelastro JM, Szabolcs M, Greene LA (2007) The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer 120:1883–1890. https://doi.org/10.1002/ijc.22469CrossRefPubMed

40.

Sears TK, Angelastro JM (2017) The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer. Oncotarget 8:84595–84609. https://doi.org/10.18632/oncotarget.21102CrossRefPubMedPubMedCentral

Titel: Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia
verfasst von: Yomna H. Youssef
Sara M. Makkeyah
Ahmed F. Soliman
Nefissa H. Meky
Publikationsdatum: 07.05.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2021
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-021-04290-6

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors

Correction to: Apoptosis of murine melanoma B16-BL6 cells induced by quercetin targeting mitochondria, inhibiting expression of PKC-α and translocating PKC-δ

Glaucocalyxin A induces apoptosis and autophagy in tongue squamous cell carcinoma cells by regulating ROS

Time-dependent population PK models of single-agent atezolizumab in patients with cancer

Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen

NCTR25 fusion facilitates the formation of TRAIL polymers that selectively activate TRAIL receptors with higher potency and efficacy than TRAIL

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie